Patents by Inventor Toru Imamura
Toru Imamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8982756Abstract: An intermittent reception control apparatus controls intermittent reception in communication between a base station apparatus and mobile station apparatuses. The intermittent reception control apparatus comprising a control unit that generates DRX parameters, which are intermittent reception parameters, and transmits the generated DRX parameters to the mobile station apparatuses. Further, the DRX parameters include information on the timing at which to cause the mobile station apparatuses to enter an active state and are common to all of the mobile station apparatuses, where the active state is a state where reception of signals transmitted from the base station apparatus is enabled. The intermittent reception control apparatus further comprising a scheduler that transmits to the mobile station apparatuses a DRX command that operates to force these apparatuses to enter an inactive state.Type: GrantFiled: January 18, 2013Date of Patent: March 17, 2015Assignee: Fujitsu LimitedInventors: Toru Imamura, Kiyoshi Miyazawa, Yoshiyuki Oota, Syuuichi Okada, Hiroaki Takashima
-
Patent number: 8697369Abstract: Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and/or betaKlotho on the surface thereof.Type: GrantFiled: April 7, 2008Date of Patent: April 15, 2014Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Masashi Suzuki, Toru Imamura, Yuriko Uehara, Kaori Motomura, Junko Oki, Syuichi Oka, Masahiro Asada, Akiko Kuramochi, Miho Kimura
-
Publication number: 20130258924Abstract: An intermittent reception control apparatus controls intermittent reception in communication between a base station apparatus and mobile station apparatuses. Further, in the intermittent reception control apparatus, a control unit generates DRX parameters, which are intermittent reception parameters, and transmits the generated DRX parameters to the mobile station apparatuses. Further, the DRX parameters include information on the timing at which to cause the mobile station apparatuses to enter an active state and are common to all of the mobile station apparatuses, where the active state is a state where reception of signals transmitted from the base station apparatus is enabled. Further, the scheduler transmits to the mobile station apparatuses a DRX command that operates to force these apparatuses to enter an inactive state.Type: ApplicationFiled: January 18, 2013Publication date: October 3, 2013Inventors: Toru IMAMURA, Kiyoshi MIYAZAWA, Yoshiyuki OOTA, Syuuichi OKADA, Hiroaki TAKASHIMA
-
Publication number: 20130174285Abstract: The present invention prepared a non-human animal in which Fgf18 gene was knocked out in a keratin-5 positive cell-specific manner using a Cre-loxP system; it provides a non-human model animal in which FGF18 expression has been inhibited in a hair follicle-specific manner to shorten the telogen phase of hair growth cycle. The non-human model animal is useful in studying hair follicles and skin, particularly hair growth occurring cyclically in hair follicle cells, and is applicable to the development of and screening for novel drugs against hair follicle or skin disorders.Type: ApplicationFiled: September 16, 2011Publication date: July 4, 2013Inventors: Toru Imamura, Miho Ueki, Yuko Oda
-
Publication number: 20120251455Abstract: A hair removing agent or a hair growth inhibiting agent is provided by determining an endogenous factor having a hair growth inhibitory activity, screening for substances having an activity similar to that of the endogenous factor or substances enhancing the activity or expression of the endogenous factor, and utilizing the physiological activities of such substances. It has been found that FGF18 inhibits hair growth. A method of screening for FGF18-like active substances, substances that promote the activity of FGF18 or substances that promote the expression of FGF18 to thereby obtain candidates for the hair growth inhibiting agent or hair removing agent is disclosed. Also disclosed is a hair growth inhibiting agent or a hair removing agent comprising, as an active ingredient, FGF18 and/or an FGF18 partial peptide, or an FGF18-like active substance and/or a substance that promotes the activity or expression of FGF18 (e.g., Digenea simplex extract).Type: ApplicationFiled: January 27, 2012Publication date: October 4, 2012Applicant: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Toru IMAMURA, Miho KIMURA, Mitsuko KAWANO, Nozomi TSUJINO, Akiko KURAMOCHI, Yuko ODA, Kaori MOTOMURA, Masashi SUZUKI, Masahiro ASADA, Azusa KAMEYAMA, Sumie TOGAYACHI, Syuichi OKA
-
Publication number: 20120214740Abstract: There is provided an FGF2 substitute-containing medicinal composition which comprises, as an active ingredient, a chimeric protein comprising the amino acid sequence of an FGF1 protein in which a partial sequence including a sequence of at least positions 62-83 within a sequence of positions 41-83 is substituted with a partial sequence at the corresponding positions in the amino acid sequence of an FGF2 protein; and the remaining region is formed of the amino acid sequence of FGF1. In particular, this medicinal composition is used for wound healing and for the prevention and treatment of radiation-induced damage, and it exhibits a pharmacological action superior to that of an FGF2 medicinal composition, and further, it can be easily formulated into a preparation.Type: ApplicationFiled: April 4, 2012Publication date: August 23, 2012Applicant: National Institute of Advanced Industrial Science and TechnologyInventors: Toru IMAMURA, Kaori MOTOMURA, Akiko KURAMOCHI, Yoshiro HANYU, Masashi SUZUKI, Masahiro ASADA, Akiko HAGIWARA, Fumiaki NAKAYAMA, Makoto AKASHI
-
Patent number: 7893028Abstract: Disclosed is a mutant protein having an altered fibroblast growth factor receptor specificity, which is produced by deleting one or more amino acid residues from the N-terminus of the amino acid sequence of naturally secreted fibroblast growth factor 18. The protein mutant can be used in a pharmaceutical composition for regulating hair regeneration or growth or a pharmaceutical composition for regulating bone or cartilage formation.Type: GrantFiled: January 9, 2007Date of Patent: February 22, 2011Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Toru Imamura, Nozomi Tsujino, Masashi Suzuki, Masahiro Asada
-
Publication number: 20100286042Abstract: There is provided an FGF2 substitute containing medicinal composition which comprises, as an active ingredient, a chimeric protein comprising the amino acid sequence of an FGF1 protein in which a partial sequence including a sequence of at least positions 62-83 within a sequence of positions 41-83 is substituted with a partial sequence at the corresponding positions in the amino acid sequence of an FGF2 protein; and the remaining region is formed of the amino acid sequence of FGF1. In particular, this medicinal composition is used for wound healing and for the prevention and treatment of radiation-induced damage, and it exhibits a pharmacological action superior to that of an FGF2 medicinal composition, and further, it can be easily formulated into a preparation.Type: ApplicationFiled: October 10, 2008Publication date: November 11, 2010Applicant: National Institute of advanced Industrial Science and TechnologyInventors: Toru Imamura, Kaori Motomura, Akiko Kuramochi, Yoshiro Hanyu, Masashi Suzuki, Masahiro Asada, Akiko Hagiwara, Fumiaki Nakayama, Makoto Akashi
-
Publication number: 20100203055Abstract: It is intended to provide a hair growth promoting agent, hair regrowth promoting agent or therapeutic for alopecia by determining an endogenous factor that inhibits hair growth and screening for substances that inhibit the activity or expression of the endogenous factor. It has been found that FGF18 inhibits hair growth. A method of screening for substances that inhibit the activity of FGF18 or substances that inhibit the expression of FGF18 to thereby obtain candidates for the hair growth promoting agent, hair regrowth promoting agent or therapeutic for alopecia is disclosed. Also disclosed is a hair growth promoting agent, hair regrowth promoting agent or therapeutic for alopecia comprising, as an active ingredient(s), a substance that inhibit the activity of FGF18 and/or a substance that inhibits the expression of FGF18 such as a partial peptide of FGF18 or a Momordica charantia hot water extract.Type: ApplicationFiled: February 19, 2008Publication date: August 12, 2010Inventors: Toru Imamura, Miho Kimura, Mitsuko Kawano, Nozomi Tsujino, Akiko Kuramochi, Yuko Oda, Kaori Motomura, Masashi Suzuki, Masahiro Asada, Azusa Kameyama, Sumie Togayachi, Syuichi Oka
-
Publication number: 20100184665Abstract: Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and/or betaKlotho on the surface thereof.Type: ApplicationFiled: April 7, 2008Publication date: July 22, 2010Inventors: Masashi Suzuki, Toru Imamura, Yuriko Uehara, Kaori Motomura, Junko Oki, Syuichi Oka, Masahiro Asada, Akiko Kuramochi, Miho Kimura
-
Publication number: 20100183733Abstract: A hair removing agent or a hair growth inhibiting agent is provided by determining an endogenous factor having a hair growth inhibitory activity, screening for substances having an activity similar to that of the endogenous factor or substances enhancing the activity or expression of the endogenous factor, and utilizing the physiological activities of such substances. It has been found that FGF18 inhibits hair growth. A method of screening for FGF18-like active substances, substances that promote the activity of FGF18 or substances that promote the expression of FGF18 to thereby obtain candidates for the hair growth inhibiting agent or hair removing agent is disclosed. Also disclosed is a hair growth inhibiting agent or a hair removing agent comprising, as an active ingredient, FGF18 and/or an FGF18 partial peptide, or an FGF18-like active substance and/or a substance that promotes the activity or expression of FGF18 (e.g., Digenea simplex extract).Type: ApplicationFiled: February 19, 2008Publication date: July 22, 2010Inventors: Toru Imamura, Miho Kimura, Mitsuko Kawano, Nazomi Tsujino, Akiko Kuramochi, Yuko Oda, Kaori Motomura, Masashi Suzuki, Masahiro Asada, Azusa Kameyama, Sumie Togayachi, Syuichi Oka
-
Patent number: 7741078Abstract: A heparin-binding protein having covalently bonded heparan sulfate sugar chains within its molecule is produced by ligating a cDNA encoding a peptide which can be modified with heparan sulfate sugar chains selectively to a cDNA encoding a heparin-binding protein and producing in an animal cell the gene product of the resultant ligated cDNA. This heparan sulfate sugar chain-modified heparin-binding protein is functionalized by covalently bonding thereto glycosaminoglycan sugar chains containing little chondroitin sulfate. For example, this heparin-binding protein is excellent in stabilities, such as thermostability, acid resistance, alkali resistance and in vivo stability. Further, the heparan sulfate sugar chain-modified heparin-binding protein is effective in cell proliferation and tissue regeneration, and has effect of regulating the physiological functions of FGFs. Thus, this heparin-binding protein is extremely useful as a medicine for preventing or treating various FGF-related diseases.Type: GrantFiled: March 31, 2005Date of Patent: June 22, 2010Assignee: National Institute of Advanced Science and TechnologyInventors: Toru Imamura, Masahiro Asada, Masashi Suzuki
-
Patent number: 7738649Abstract: A computer system 1 has a PBX 2, a terminal device 3, and a management server 4. The PBX 2 has a line controller, an extension controller 2b, an interface, a memory that stores identification information and an enciphered file, a decoder that decodes the enciphered file, a comparator that compares the identification information and the enciphered file decoded by the decoder, and a controller. The terminal device 3 reads the identification information from the PBX 2 and transmits that to the management server 4. The management server 4 has an authenticator that receives a request for authentication when the terminal device 3 logs in, an issuer that issues the enciphered file according to the identification information, and a database that stores the issue date in correlating with the identification information.Type: GrantFiled: July 12, 2005Date of Patent: June 15, 2010Assignee: Panasonic CorporationInventors: Ryota Nonaka, Koji Abe, Shinya Isumi, Toru Imamura
-
Publication number: 20090286965Abstract: Disclosed is a mutant protein having an altered fibroblast growth factor receptor specificity, which is produced by deleting one or more amino acid residues from the N-terminus of the amino acid sequence of naturally secreted fibroblast growth factor 18. The protein mutant can be used in a pharmaceutical composition for regulating hair regeneration or growth or a pharmaceutical composition for regulating bone or cartilage formation.Type: ApplicationFiled: January 9, 2007Publication date: November 19, 2009Inventors: Toru Imamura, Nozomi Tsujino, Masashi Suzuki, Masahiro Asada
-
Patent number: 7589060Abstract: It is intended to elucidate the effect of promoting hair follicle growth and to provide the following therapeutic agents for hair-related problems (1) to (3): (1) a hair growth promoting agent, comprising as an active ingredient an expression vector incorporating a full-length FGF-18, a partial peptide thereof, or a cDNA encoding the full-length FGF-18 or the partial peptide; (2) a hair regrowth promoting agent, comprising as an active ingredient an expression vector incorporating a full-length FGF-18, a partial peptide thereof, or a cDNA encoding the full-length FGF-18 or the partial peptide; and (3) a therapeutic agent for alopecia, comprising as an active ingredient an expression vector incorporating a full-length FGF-18, a partial peptide thereof, or a cDNA encoding the full-length FGF-18 or the partial peptide.Type: GrantFiled: September 8, 2005Date of Patent: September 15, 2009Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Toru Imamura, Mitsuko Kawano, Akiko Kuramochi, Masashi Suzuki, Masahiro Asada
-
Patent number: 7444391Abstract: A data terminal, a data distributing system, and an Internet telephoning system are provided where desired data such as advertisements can selectively be determined and used for enjoying its relevant services. The data terminal receives a summary of service data from a data provider apparatus over the Internet, and if desired, demands the data provider apparatus to provide the service data over the Internet. The service data from the data provider apparatus may selectively be received in at least one of an audio form, a text form, and a video form at the data terminal. The service data may be advertisement data, commercial product data, and entertainment data such as music, movies, and games. The entertainment data may selectively be presented as at least one of the title, the artist name, the cost, and a trial sample piece of the content.Type: GrantFiled: April 30, 2004Date of Patent: October 28, 2008Assignee: Matsushita Electric Industrial Co., Ltd.Inventors: Tomiya Miyazaki, Kazuo Yahiro, Toru Imamura, Masafumi Tanaka, Yutaka Takeda, Keisuke Ogata, Takuji Tsujigawa, Akitoshi Aritaka
-
Publication number: 20080139469Abstract: It is intended to elucidate the effect of promoting hair follicle growth and to provide the following therapeutic agents for hair-related problems (1) to (3): (1) a hair growth promoting agent, comprising as an active ingredient an expression vector incorporating a full-length FGF-18, a partial peptide thereof, or a cDNA encoding the full-length FGF-18 or the partial peptide; (2) a hair regrowth promoting agent, comprising as an active ingredient an expression vector incorporating a full-length FGF-18, a partial peptide thereof, or a cDNA encoding the full-length FGF-18 or the partial peptide; and (3) a therapeutic agent for alopecia, comprising as an active ingredient an expression vector incorporating a full-length FGF-18, a partial peptide thereof, or a cDNA encoding the full-length FGF-18 or the partial peptide.Type: ApplicationFiled: September 8, 2005Publication date: June 12, 2008Inventors: Toru Imamura, Mitsuko Kawano, Akiko Kuramochi, Masashi Suzuki, Masahiro Asada
-
Publication number: 20080119403Abstract: A heparin-binding protein having covalently bonded heparan sulfate sugar chains within its molecule is produced by ligating a cDNA encoding a peptide which can be modified with heparan sulfate sugar chains selectively to a cDNA encoding a heparin-binding protein and producing in an animal cell the gene product of the resultant ligated cDNA. This heparan sulfate sugar chain-modified heparin-binding protein is functionalized by covalently bonding thereto glycosaminoglycan sugar chains containing little chondroitin sulfate. For example, this heparin-binding protein is excellent in stabilities, such as thermostability, acid resistance, alkali resistance and in vivo stability. Further, the heparan sulfate sugar chain-modified heparin-binding protein is effective in cell proliferation and tissue regeneration, and has effect of regulating the physiological functions of FGFs. Thus, this heparin-binding protein is extremely useful as a medicine for preventing or treating various FGF-related diseases.Type: ApplicationFiled: March 31, 2005Publication date: May 22, 2008Applicant: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCEInventors: Toru Imamura, Masahiro Asada, Masashi Suzuki
-
Patent number: 7282481Abstract: A heparin-binding protein functionalized by covalently bonding thereto a sugar chain, a method for producing the protein and a pharmaceutical composition containing the protein as an active ingredient, as well as a method of functionalizing a natural protein having no sugar chain by covalently bonding thereto a sugar chain.Type: GrantFiled: November 23, 2005Date of Patent: October 16, 2007Assignee: Director-General of Agency of Industrial Science and TechnologyInventors: Toru Imamura, Masahiro Asada, Syuichi Oka, Masashi Suzuki, Atsuko Yoneda, Keiko Ota, Yuko Oda, Kazuko Miyakawa, Noriko Orikasa, Chie Asada, Tetsuhito Kojima
-
Publication number: 20070207545Abstract: In the present invention, in order to expand the range of drug resistance markers available for use in a transgenic vector for animal cells, an expression vector comprising a multicloning site identical to those of the existing vectors and drug resistance marker genes different from those of the existing vectors is produced. The present invention provides an animal cell expression vector containing a multicloning site and a puromycin resistance gene or a blasticidin S resistance gene as a drug resistance marker gene, the expression of which is controlled by SV40 ori and SV40 pA.Type: ApplicationFiled: November 22, 2006Publication date: September 6, 2007Inventors: Masahiro Asada, Toru Imamura, Emi Honda